Carrimycin Firstly Appeared in the Official List of Effective Drugs Against COVID-19

Updated: Dec 18, 2020 01-04-2020

Original title :Carrimycin Firstly Appeared in the Official List of Effective Drugs Against COVID-19, With the Only Production Line in Shanghai

April 1, China News For the first time, Carrimycin produced in Songjiang District appeared on the official list of effective drugs against COVID-19.

On March 26, the State Council Information Office of the PRC held a press conference where Xu Nanping, the vice minister of the Ministry of Science and Technology, said that the Chinese science and technology community had done a large amount of work around effective drug development and clinical treatment during the fight against the epidemic, and drugs such as chloroquine phosphate, favipiravir, and Carrimycin had shown certain therapeutic effects in clinical studies.

The relevant clinical trials currently published show that Carrimycin can remove the Corona Virus from the human body promptly and effectively, improve clinical symptoms and lung inflammation significantly, and is extremely safe compared to other drugs. Especially for severe and critically ill patients, virus recovery and patients with failed antiviral therapy, it has obvious effect without obvious adverse reactions.

These days, the Carrimycin production line of Shanghai Tonglian Pharmaceutical Co., Ltd. in Songjiang Economic and Technological Development Zone is extremely busy and workers are working by extra shifts and hours to produce Carrimycin. “This is the only production line of Carrimycin in the world.” Said He Jianxin proudly, Deputy Manager of Shanghai TongLian Pharmaceutical Co., Ltd.

When the workers are working overtime to produce Carrimycin, the company’s anti-epidemic team is sticking to their posts in Wuhan, which is more than 800 kilometers away from Songjiang, to cooperate with Wuhan Jinyintan Hospital, Wuhan Pulmonary Hospital, People’s Hospital of Wuhan University and other hospitals for clinical trials of drugs.

Celiromycin, emerging well in the fight against COVID-19, was officially approved to the market by the China Food and Drug Administration in June 2019. Although it has not been on the market for a long time, it is extremely “prominent”. According to He Jianxin, Carrimycin, jointly developed by Shenyang Tonglian Group Co., Ltd. and the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, is the world’s first class 1 new drug developed by using synthetic biology technology with independent Chinese intellectual property. At present, it has obtained 16 national invention patents, three of which have been applied to PCT member states, and 41 authorizations. It is in the list of the national “863” major science and technology projects, a key product of Chinese manufacturing 2025, and gained special support from the “Major New Drug Innovation of the National Science and Technology Major Projects”, and was rated as China Top 10 Advancement Projects in pharmaceutical biotechnology in 2019.

The development of Carrimycin, which was entrusted with a mission at a critical and difficult moment of fighting against COVID-19 can be described as “racing against time.” On January 22, the molecular simulation experiment by Shenyang Pharmaceutical University was completed; on February 10, the report of the pharmacodynamics and in vitro screening test of the Chinese Academy of Medical Sciences was completed; on February 15, the units of the team leaders Beijing Youan Hospital, Capital Medical University and Huangshi Central Hospital passed the ethical review; on the same day, trial registration was performed in the Chinese Clinical Trial Registry, the first batch of drugs used for trials arrived at the sub center, and the first batch of subjects were enrolled in Huangshi Central Hospital.

“Clinical trials of Carrimycin in 9 hospitals across the country are coming to an end, and the company will go all out to facilitate the clinical application of drugs. At the same time, related registration and access work goes on simultaneously, aiming to enter theinternational market as soon as possible. According to He Jianxin, for domestic COVID-19 patients, the company will provide medicines for domestic COVID-19 patients free of charge through hospitals, which also reflects the sense of social responsibility of enterprises in the G60 High-Tech Corridor in the Yangtze River Delta. (The End)

Source: China News

21 views0 comments